Instrument NameJohnson & JohnsonInstrument Symbol(JNJ-N)

Instrument ExchangeNYSE

You'll also like these stocks for their track record of earnings growth.

Stocks/ETFs to Consider A Trump presidency could impact markets and sectors in particular ways based on policies he has previously supported, though unforeseen factors may also influence outcomes. If we look at historical trends and policy priorities, here are some sectors and types of investments that may do well: 1....

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

Data show plaintiffs’ lawyers spent more than $778,000 to air more than 4,600 TV ads soliciting the claims, the most spent on talc ads since August, 2023, according to X Ante founder Rustin Silverstein

AI could soon transform the medical technology industry, and this market leader may continue to dominate.

These healthcare stocks have fantastic dividend track records.

In 1980, around five dozen publicly traded companies held the highest possible credit rating (AAA) from Standard & Poor's. Today, there are only two left.

These three Vanguard ETFs are worth considering for the long term.

Fewer contenders means fewer constraints on expanding market share.

U.S. stocks edged back from their all-time highs as some of the steam came out of Wall Street’s long, record-breaking rally

Investors looking for dividend stocks at reasonable valuations have come to the right place.

These companies' longtime shareholders have generally been rewarded.

These stocks could deliver big over the long term.

Johnson & Johnson's latest financial checkup shows it's still in excellent health.

Top Stock News Alimentation Couche-Tard Inc: Artisan Partners urged Seven & i Holdings to let Couche-Tard negotiate its $47 billion takeover bid, criticizing a recent restructuring plan as inadequate. ASML Holding NV: ASML forecasted lower sales for 2025 due to ongoing weakness in the semiconductor market, resulting in a significant...

Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026.

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.

JNJ earnings call for the period ending September 30, 2024.

A survey of North American equities heading in both directions

Futures tied to Canada's main stock index fell on Tuesday due to lower crude prices, with investors ...

Johnson & Johnson earned $2.42 per share on an adjusted basis in the third quarter, falling 9% on the previous year but beating analysts’ average estimates of $2.21

Johnson & Johnson (JNJ) is set to release its Q3 earnings results on Tuesday, October 15th, before the market opens. Investors and analysts are keen to see how the healthcare giant has performed amidst ongoing challenges and opportunities within its MedTech and pharmaceutical divisions. The earnings report is expected to...

December S&P 500 E-Mini futures (ESZ24) are trending down -0.03% this morning as investors looked ahead to quarterly reports from more big banks while also awaiting remarks from Federal Reserve officials.

Many of the top exchange-traded funds (ETFs) in the market these days rely heavily on overpriced tech ...

Earnings season is back, with a couple of big names due to report this week including some of the major banks.